Table 2.

Study design and demographic profile of patients included in the selected studies.

Details	Clozapine (N = 9)	Non-Clozapine (N = 14)
Study Design
Randomized Control Trials	2	4
Case Series	1	0
Open-Label Trials	6	10
Demographic Details
Target Population	98	1084
Age	35.7	32.85
Gender*(female/male)	39/56	529/456
Duration of Illness**(yr)	15.36	11.11
Dosage of drug***(mg/day)	392.18	Chlorpromazine = 235.99
		Flupenthixol = 21.64
		Risperidone = 6.26
		Loxapine = 36.7
No. of ECT treatments****	13.44	13.2

*Gender-specific data for [27, 28] was not available.

**Duration of Illness for [28, 29, 30, 31, 32]and [33] was not available.

***Dosage of drug for [29, 34] was not available.

****No. of ECT treatments for [35] was not available.